Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-2.24
Price to sales ratio
185.88

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2010
AGL
agilon health, inc. Common Stock
116.21 USD+1.09%+7.19%+2.07%+4996.93%1.94 B USD
2025
SNDA
Sonida Senior Living, Inc. Common Stock
40.25 USD-0.52%-2.12%+14.28%+55.71%1.91 B USD
2125
HCSG
Healthcare Services Group, Inc. - Common Stock
24.04 USD+1.05%-2.51%+6.28%+29.67%1.65 B USD
2128
SRXH
SRX Health Solutions, Inc. Common Stock
2.78 USD+31.13%+63.53%+1753.33%+2036.82%1.64 B USD

Frequently asked questions about COMPASS Pathways Plc - American Depository Shares

What is the COMPASS Pathways Plc - American Depository Shares stock price today?

The current price of COMPASS Pathways Plc - American Depository Shares (CMPS) is 13.19. Over the past 24 hours, the stock has changed by -3.30%. Follow the CMPS chart for real-time price dynamics.

What is the stock ticker of COMPASS Pathways Plc - American Depository Shares?

COMPASS Pathways Plc - American Depository Shares trades under the ticker CMPS. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is COMPASS Pathways Plc - American Depository Shares stock going up?

CMPS has changed by +12.06% over the last week, +6.37% over the last month, and +107.06% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was COMPASS Pathways Plc - American Depository Shares net income for the last quarter?

COMPASS Pathways Plc - American Depository Shares reported net income of 91.2 M for the last quarter. The previous quarter showed -93.88 M, which means net income changed by +197.15%.

How many employees does COMPASS Pathways Plc - American Depository Shares have?

As of the latest available data, COMPASS Pathways Plc - American Depository Shares has 156 employees. Workforce size can provide additional context about the company's scale and operations.

What is COMPASS Pathways Plc - American Depository Shares EBITDA?

COMPASS Pathways Plc - American Depository Shares EBITDA is -43.38 M, and its EBITDA margin is 5 893.89%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy COMPASS Pathways Plc - American Depository Shares stock?

You can buy COMPASS Pathways Plc - American Depository Shares (CMPS) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in COMPASS Pathways Plc - American Depository Shares stock?

Investing in COMPASS Pathways Plc - American Depository Shares requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the CMPS chart and related analysis on metatrader.com as part of your research.

COMPASS Pathways Plc - American Depository Shares

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine. Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use.

News